Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 490 clinical trials
Determinants of Neonatal Anemia in Women Carrying Multiples

Determinants of neonatal anemia will be identified. Inflammatory markers will be measured in all blood samples and related to outcomes. Stable iron isotopes will be given to a subset of women to assess maternal Fe absorption and fetal Fe uptake.

Accepts healthy volunteers
  • 0 views
  • 10 Jan, 2025
  • 2 locations
Teaching Novel Values-Based Skills to Improve Long-Term Weight Loss

This NIDDK funded R01 project is a randomized controlled clinical trial to compare the efficacy of an intervention based on Acceptance and Commitment Therapy (ACT) and a Self-Regulation (SR) intervention on weight loss maintenance over a 30-month period. All participants will first complete a well-validated online weight loss intervention (months …

body mass index
acceptance and commitment therapy
  • 0 views
  • 19 Feb, 2024
Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies PART B: the second part will include 3 expansion cohorts of 15 patients: B1: anti-PD-1 refractory advanced NSCLC cohort …

cancer
conventional treatment
measurable disease
EGFR
mdx-ctla-4
  • 0 views
  • 19 Feb, 2024
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Since the study is "blinded," patients and their doctors will not know whether a patient gets brentuximab vedotin or placebo. All patients in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

measurable disease
large b-cell lymphoma
brentuximab vedotin
brentuximab
systemic therapy
  • 0 views
  • 19 Feb, 2024
89Zr-atezolizumab PET Scan and Lobular Breast Cancer

Ten patients with lobular metastatic breast cancer, who are included in the GELATO trial at the UMCG, are eligible for the ImaGelato study. All patients will undergo two Zirconium-89 (89Zr)-atezolizumab positron emission tomography (PET) scans, one at baseline and one after two doses carboplatin induction treatment.

  • 0 views
  • 19 Feb, 2024
Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab

This is an open-label, multicenter study that includes a main study for all participants enrolled and an optional cerebrospinal fluid (CSF) sub-study. Self-identified African American (AA) and Hispanic or Latin American (HA) participants with a diagnosis of relapsing multiple sclerosis (RMS) will be enrolled.

  • 0 views
  • 19 Feb, 2024
Benefits of Exercise in Alzheimer's Disease

Ultimately, the hope is that the results of this study could be used to facilitate exercise programs for patients. Enrollment is completely voluntary and all personal data obtained will remain confidential.

aerobic exercise
behavioral symptoms
cognitive assessment
neuropsychological test
alzheimer's disease
  • 4 views
  • 19 Feb, 2024
  • 1 location
Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

The infection of Covid-19 is mediated through binding of the Spike protein to the ACEII receptor, and the viral replication depends on molecular mechanisms of all of these viral proteins. This trial proposes to develop and test innovative Covid-19 minigenes engineered based on multiple viral genes, using an efficient lentiviral …

  • 0 views
  • 19 Feb, 2024
Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA (reiMMAgine)

All subjects will be monitored closely for safety for the first year of the study and then annually for an additional 4 years.

  • 0 views
  • 19 Feb, 2024
  • 1 location
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

However, a large number of clinical studies have shown that about 20% of patients with B-ALL and 50% of patients with B-NHL cannot achieve complete remission (CR) after CD19-CAR-T treatment. Targeting tumor microenvironment is an important new method to overcome the drug resistance of CAR-T cells.

pet/ct scan
ct scan
b-cell acute lymphoblastic leukemia
flow cytometry
antibody therapy
  • 0 views
  • 19 Feb, 2024